Azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) vs placebo
Induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2 g/day) · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether azo‐bonded and delayed‐release mesalamine (2 ‐ 3.2 g/day) changes induction of remission (CDAI < 150 + decrease >=70) ‐ Asacol (3.2… compared with placebo (very low certainty).
1 finding from 1 review
- Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 2.03 [0.75, 5.45]1 study · 38 participantsVery low